Latest Infant Formula News

Bubs Australia has appointed Paul Jensen as its new Independent Chair and Joe Coote as Managing Director and CEO, signaling a fresh leadership chapter for the infant formula and dairy company.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.

The a2 Milk Company reported a robust 21% rise in net profit for FY25, driven by strong growth in China and the USA, alongside a landmark full-year dividend declaration and major supply chain restructuring.

The a2 Milk Company reported record FY25 results with $1.9 billion in sales and declared its first-ever dividends, while advancing a major supply chain overhaul through a key New Zealand manufacturing acquisition and divestment.

Aumake Limited reported a remarkable 213% surge in quarterly cash receipts, driven by exclusive distribution agreements and strategic cost reductions, setting the stage for profitability in FY26.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

Australian Dairy Nutritionals Limited has reported a record-breaking quarter with total revenue soaring 119% year-on-year, driven by an 801% jump in nutritional powder sales and expanded distribution in China.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Clover Corporation has upgraded its FY25 earnings forecast, expecting net profit after tax to exceed market consensus by around 20%, driven by strong sales and operational improvements.

Australian Dairy Nutritionals Limited reported a record $736k revenue from nutritional powders in Q3 FY25, driven by its new Future brand launch in China and expanding sales in Vietnam. The company’s strategic partnerships and premium product positioning signal a pivotal shift in its growth trajectory.